HI
UNCY icon

Harbour Investments’s Unicycive Therapeutics UNCY Stock Holding History

Harbour Investments’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$658 Hold
100
– – ﹤0.01% 4200
2025
Q4 		$577 Hold
100
– – ﹤0.01% 3535
2025
Q3 		$436 Hold
100
– – ﹤0.01% 3531
2025
Q2 		$477 Buy
+100
New +$618 ﹤0.01% 3382

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harbour Investments's UNCY Position: Q1 2026 in Review

Harbour Investments held its Unicycive Therapeutics (UNCY) position steady in Q1 2026 at 100 shares worth $658. The position accounts for ﹤0.01% of the portfolio, ranked #4200.

Harbour Investments first reported a position in UNCY in Q2 2025 and has held it in 4 quarters since. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Harbour Investments held 100 shares of Unicycive Therapeutics worth $658 as of Q1 2026.
  • Harbour Investments left its Unicycive Therapeutics share count unchanged in Q1 2026.
  • Unicycive Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #4200 holding.
  • Harbour Investments first reported a position in Unicycive Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.